Choose a language and wait for the translated text.
Shots:
Seawolf Therapeutics has emerged from stealth with $100M, comprising a seed round led by Versant Ventures & a Series A from Versant, MPM BioImpact & Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Alexandria Venture Investments, Pathway to Cures & others
Seawolf also entered into a multi-target research collaboration & exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders & other indications, making it eligible for up to $1.2B in R&D & commercial milestones, plus tiered royalties
Funds will advance its redosable LNP-based DNA delivery platform, TRIDENT, which has shown sustained protein expression above therapeutic levels in primates at safe & well-tolerated doses; its lead proprietary program for metabolic diseases is advancing to development candidate
Ref: Business Wire | Image: Seawolf Therapeutics | Sanofi | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Seawolf Therapeutics Debuts with $100M and Enters into an Up to $1.2B Collaboration with Sanofi to Develop DNA Medicines appeared first on PharmaShots.
Seawolf Therapeutics Debuts with $100M and Enters into an Up to $1.2B Collaboration with Sanofi to Develop DNA Medicines | PharmaVoice